Overview

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Status:
Recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
This research study is comparing the use of a new form of hormonal therapy used with radiation as a possible treatment for intermediate risk prostate cancer. More specifically, this research would help determine whether this new form of hormonal therapy is as effective as the standard hormone therapy while also preserving erectile function.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Bayer
Decipher Biosciences
GenomeDx Biosciences Corp
Treatments:
Bicalutamide
Deslorelin
Triptorelin Pamoate